Second, it announced that Roche received European Commission marketing authorization for OCREVUS® co-formulated with ENHANZE® for treating relapsing multiple sclerosis (RMS) and primary ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in ...

“Governor Muriithi was elected on that manifesto that was included in the CIDP. The need by the people was projected ... A few days later, a contractor came, dug some trenches then disappeared,” said ...

On Wednesday, Morgan Stanley (NYSE:MS) began coverage on CSL Ltd (OTC ... FcRn receptor agonists in treating chronic inflammatory demyelinating polyneuropathy (CIDP). Additionally, the firm is ...

Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for ...

CIDP is often considered the chronic form of Guillain-Barré Syndrome and, as such, can be more problematic in that it lasts longer, causes more damage and is more difficult to recover from. CIDP ...

CIDP significantly affects daily life, with many patients needing mobility aids and caregiver support, impacting employment and quality of life. A real-world survey showed 22% of CIDP patients ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with ...

Today’s results show that deeper IgG reduction leads to deeper responses in MG and CIDP. Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction ...